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Synopsis
Stem cell transplantation (SCT) is an established first-line or adjunctive therapy for a variety of 
neonatal and adult diseases. New evidence in preclinical models as well as a small number of 
human studies show the potential utility of SCT in neuroprotection and in the modulation of 
inflammatory injury in at risk-neonates. In this review we briefly summarize current 
understanding of human stem cell biology during ontogeny and present recent evidence supporting 
SCT as a viable approach for post-insult neonatal injury.
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Introduction
Stem cell transplantation (SCT) is an established first-line or adjunctive therapy for a variety 
of neonatal diseases, including those involving inborn errors of metabolism, types of 
primary immune deficiencies, certain neutrophil disorders, and hematologic malignancies 
such as neonatal leukemia. The utility of SCT in these and related conditions have been 
extensively discussed in the literature, and are beyond the scope of the present review1–6. 
We here briefly summarize current understanding of human stem cell biology during 
ontogeny and present recent evidence of the potential role of SCT for the treatment of post-
insult neonatal injury.
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Stem Cell Biology: A Brief Review
Stem cell theory: Pluripotent stem cells and tissue specific somatic stem cells
Two main types of stem cells have been described: Pluripotent stem cells (PSCs) and 
somatic stem cells. The PSCs are multipotent stem cells that can differentiate into all cell 
types in the body and include embryonic stem cells (ESCs) and inducible pluripotent stem 
cells (iPSCs). Tissue specific somatic stem cells give rise to organ-specific cell types. 
Embryonic stem cells (ESCs) are first established from the inner cell mass of the blastocysts 
in a fertilized egg7–9. In vitro studies have shown that cultured ESCs display self-renewal 
ability and have the capacity for multi-lineage differentiation. ESCs can differentiate into 
cell types that include all three germ layers, and in vivo studies have shown that ESCs can 
form teratomas when inoculated into immune deficient mice. Murine studies have shown 
that when a fertilized egg is injected with ESCs and implanted into a pseudo-pregnant dam, 
ESC-derived cells contribute to all embryonic cell types, forming a chimeric animal. The 
multi-lineage differentiation ability of ESCs both in vivo and in vitro highlights their 
potential utility for stem cell therapies (SCT). However, this therapeutic potential is 
accompanied by ethical problems since ESCs can be derived only from fertilized eggs.
More recently, embryonic stem (ES)-like pluripotent stem cells have been established from 
postnatal mouse testis and adult mouse/human somatic cells following the introduction of 
“stemness genes” such as Oct4, c-myc, Sox2, and Klf410–12. These ‘inducible pluripotent 
stem cells’ (iPSC) overcome the ethical problems associated with ESCs; thus, iPSC biology 
and its possibilities for clinical applications have been the focus of intensive research. 
However, although mESC/iPSC have been shown to differentiate into somatic stem cells in 
vivo in chimeric animals, the induction of tissue-specific somatic stem cells from iPS cells 
remains a challenging problem. One primary reason for this is the difficulty in maintaining 
iPS-derived stem cells in cell lineages that require rapid cell cycling of their progenitors to 
maintain cellular homeostasis (such as in the blood, skin, and skeletal muscles). Thus, the 
use of iPSC to produce functional progenitor cells, or even mature cells, may be most 
successful when cellular targets have relatively slow intrinsic cycling rates and thus do not 
require rapid somatic cellular replacement. Recent major advances in iPS-derived cell 
therapy have been reported in a non-human primate spinal injury model and in a clinical trial 
of iPS-derived retinal pigment epithelium replacement13;14.
According to currently accepted stem cell theory, each tissue in the body is maintained by 
tissue-specific stem cells with the capacity for self-renewal and specific lineage 
differentiation. During embryonic organogenesis, stem cells differentiate into lineage cells 
that form specific tissues. These stem cells are maintained in the tissues even during 
adulthood: for example, cell types such as hair, skin, melanocytes, blood, muscle, intestinal 
epithelium, and sperm are continuously regenerated by tissue specific stem/progenitor cells. 
Although the healthy liver does not typically undergo tissue regeneration, if damaged the 
liver becomes a regenerative organ. Stem/progenitor cells, which have been identified in 
every tissue/organ, reside in a special microenvironment, called a niche, which facilitates the 
maintenance of self-renewal capacity. Although the brain and nervous system were not 
previously considered to have regenerative abilities, recent studies have identified stem/
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progenitor cells and their niches even in adult animals15–17. These cells may play a role in 
the maintenance of tissue homeostasis and can acquire the ability to produce lineage-specific 
cells for tissue regeneration following injury.
Recent technological advances have facilitated the identification, isolation, and purification 
of human somatic stem cells. The hematopoietic stem cell (HSC), the first stem cell to be 
experimentally proven in humans, resides in the bone marrow and is thus readily accessible 
for clinical purposes. Blood stem/progenitor cells have a homing ability that enables their 
migration to and engraftment in the bone marrow of the recipient when administered 
intravenously, without the need for surgical “implanting” procedures. HSC transplantation 
has been successfully performed to treat a wide spectrum of hematopoietic disorders and 
malignancies.
The hematopoietic system is the best in vivo example of the somatic stem cell theory. Post-
transplantation bioassays have defined HSCs and confirmed their self-renewal and multi-
lineage blood cell differentiation capacities. Long term (LT-) HSCs exhibit prolonged 
engraftment in recipient BM (more than 4 months in mice, 4–8 months in humans) and are 
secondary transplantable. LT-HSCs sit at the apex of the hematopoietic hierarchy system 
(Figure) and give rise to short term (ST)- HSCs, or multipotent progenitor cells (MPP), that 
engraft recipient BM for less than 4 months. ST-HSCs/MPPs differentiate into lymphoid-
primed progenitor cells (LMPP) and common myeloid progenitor cells (CMP) in mice, or 
multilymphoid progenitors (MLPs) and CMP in humans. Murine LMPPs and human MLPs 
are primarily lymphoid progenitors that produce B and T cells but still retain myeloid 
potential. The more lineage-specific CMPs give rise to erythrocyte, megakaryocytes, 
granulocytes, monocytes/macrophages, and dendritic cells. Thus, HSCs produce a wide 
variety of blood cells and are maintained by self-renewal mechanisms within the 
hematopoietic BM niche.
Since the discovery of HSCs in umbilical cord blood (CB) and the first successful CB 
transplantation in a patient with Fanconi anemia in 1989, CB has been widely used for HSC 
transplantation in addition to BM or mobilized peripheral blood (PB) HSCs18–20. In this 
chapter, we will describe the development of HSCs in in the human embryo/fetus and other 
stem/progenitor cells found in CB. We will also discuss ongoing and possible clinical 
applications utilizing CB and related stem cells.
Hematopoietic Stem Cells
Human Embryonic HSC Development in Mice and Humans
The first HSCs are produced during embryogenesis, but are also found in the adult BM 
niche at steady state. Human cord blood contains proportionately greater numbers of 
circulating CD34+ HSCs than does the peripheral blood of adults21.
Developmental hematopoiesis has been well described in mice, an ideal model given a short 
(19-day) gestation.22. The first site of hematopoiesis, the extra-embryonic yolk sac (YS) at 
embryonic day (E) 7.5, consists of mainly large erythroid cells, called primitive 
erythrocytes23. Primitive erythrocytes express embryonic-type hemoglobin molecules and 
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have a large nucleus24. Erythroid progenitor cells that express adult type hemoglobin 
molecules are called definitive erythroid progenitor cells and are detected from E8.0 YS 
together with myeloid progenitors25. The progenitors of definitive erythroid cells and 
myeloid cells are called erythro-myeloid progenitors (EMPs) and are produced mainly in the 
YS during E8 to 1026. The first murine HSCs that can reconstitute lethally irradiated adult 
marrow by transplantation assay are detectable at E11 in the aorta-gonado-mesonephros 
(AGM) region27;28. These EMPs and HSCs are all derived from endothelial cells, called 
hemogenic endothelial cells (HECs)29–32. The transition from HECs to hematopoietic cells 
occurs between E7.5 to E11.533. HSCs produced by the HECs in the aortic area migrate into 
the fetal liver and placenta, where they subsequently undergo a massive expansion34–36. 
HSCs migrate into the spleen and bone marrow at the end of gestation, just before birth, and 
HSCs ultimately reside in the bone marrow niche to maintain hematopoiesis throughout the 
life.
Similarly, in humans, hematopoiesis is first observed in the YS as early as embryonic day 18 
(presomite stage)37. Primitive and definitive hematopoiesis are observed in the YS up to 7 
weeks of gestation and are gradually replaced by fetal liver hematopoiesis, which has been 
initiated by gestational day 3038;39. Hematopoietic clusters expressing CD34 and CD45 
have been observed in the ventral wall of the dorsal aorta beginning on day 2740–42. These 
clusters rapidly increase in size and can attain several hundreds of cells by day 36. The intra-
aortic CD34+ cells express important hematopoietic transcriptional factors including tal/
SCL, c-myb, and GATA2, as well as CD143 (angiotensin-converting enzyme), which is 
known to enrich HSC activity in CB CD34+ cells43;44. Studies have shown that NOD/SCID/
IL2Rγcnull (NSG) mice can be reconstituted with human HSC45, and active human colony 
forming activities are detectable in the recipient mouse bone marrow. The first human HSCs 
shown to reconstitute NSG mice for up to 8 months have been identified in the day 32 AGM 
region46. These AGM-derived HSC are detectable in the peripheral blood of recipient mice 
3 months post transplantation. Their numbers gradually increase over time, reaching up to 
90% of chimerism by 8 months following transplantation. Human AGM-derived cells also 
reconstitute secondary recipient mice and display self-renewal capacity (a key measure of 
stem cell function), generating at least 300 daughter HSCs46. HSC in the AGM region 
express CD34, CD45, VE-cadherin, c-kit, thy-1, and endoglin, but not CD3847. Since VE-
cadherin is an endothelial specific marker, these observations suggest that human HSCs are 
derived from HECs as has been observed in murine HSCs. Fetal liver HSCs are first 
detected on gestational day 42 and express CD34, CD45. VE-cadherin is also initially 
expressed on these HSCs, although this is lost after 10 weeks of gestation48.
Circulating CD34+ HSCs are found in both full term and preterm CB49;50. The proportions 
of CD34+ cells in preterm CB are generally higher than in full term CB, although the 
absolute numbers of CD34+ cells reported has been variable. While preterm CB CD34+ 
cells exhibit higher colony forming ability than full term CB CD34+ cells49, preterm CD34+ 
cells may have lower repopulating ability48. The ability of transplanted CD34+ cells to 
repopulate the bone marrow in patients with severe combined immune deficiency (SCID) 
has been shown to correlate with the expression level of CXCR4, a surface receptor 
involved in cellular migration, or homing, to the bone marrow39. Thus functional differences 
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between preterm and term CD34+ cells may be linked to a relative developmental deficiency 
of CXCR4 in preterm CD34+ cells49.
Mesenchymal stem cells (MSCs)
Original observations showed that implantation of BM cells (without bone) into non-
hematopoietic tissues (such as under skin or peritoneal cavity) induced the development of 
reticular tissue followed by bone formation that could sustain ectopic hematopoiesis51–53. 
This ectopic bone formation is derived from a non-hematopoietic cell population that forms 
a clonal fibroblastic colony in vitro, the CFU-F54. The progeny of CFU-F contribute to bone 
formation following transplantation and can differentiate into multiple skeletal tissues 
including bone, cartilage, adipose tissue, and fibroblastic tissue in vivo. This rare BM 
population was first named an osteogenic stem cell or a BM stromal stem cell55;56. The 
discovery of this cell type was important in that it identified the presence of a second stem 
cell population in the BM in addition to HSCs. The currently used term, mesenchymal stem 
cell (MSC), was first proposed in 1991 based on the capacity to differentiate into cells of the 
mesenchymal lineage (bone, cartridge, tendon, ligament, BM stroma, adipocytes, dermis, 
muscle, and connective tissue)57. However, the “multipotency” of MSCs remains 
controversial56;58. Furthermore, while MSCs are often referred to as “stem cells”, they do 
not meet strict criteria regarding self-renewal capacity and multilineage potential at the 
single cell level55. A more conservative definition of MSCs (mesenchymal stromal cells59 or 
skeletal stem/progenitors60) include the following: 1) They possess CRU-F that can form 
fibroblastic colonies in vitro; 2) They have the capacity to differentiate into adipocytes, 
osteocytes, and chondrocytes in vivo and in vitro; and 3) They support hematopoietic 
development.
MSCs can be derived from embryonic limbs, postnatal BM, umbilical cord blood and other 
tissues in mouse and man51;57;61–63, including the perivascular area or BM sinusoids64. 
Their developmental origins are primarily from mesoderm but they also originate in part 
from neuroepithelium65. MSCs express unique surface antigens including Sto-1, CD271, 
CD146, but lack hematopoietic and endothelial markers (CD45, CD14, CD11b, CD79, 
CD19, HLA-DR, CD34, and CD31).
MSC exhibit poor engraftment capacity following intravenous injection, and the small 
number that do engraft survive for only a short time in the recipient animals66. Despite this 
shortcoming, MSCs may be useful for: 1) Direct cell replacement for tissue regeneration; 
and 2) Indirect effects on damaged tissue related to MSC secretion of immunosuppressive 
factors. The therapeutic benefit of MSCs appears to be greatest for the treatment of 
inflammatory diseases through the release of anti-inflammatory cytokines.
Endothelial progenitors: endothelial colony forming cells (ECFC)
The first putative endothelial progenitors were isolated from human adult PB in 1997 by 
Asahara et al.67. The major discovery that endothelial progenitor cells (EPCs) circulate in 
the peripheral blood led to the concept that these “EPCs” contribute to the repair of vascular 
injuries. However, this nomenclature was unfortunate, as it has created long-standing 
confusion regarding the true definition of “EPCs”: the cells originally defined as EPCs have 
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since been designated as hematopoietic cells, not endothelial cells68. The term that now 
most reliably defines circulating endothelial progenitors obtained from human PB or CB is 
endothelial colony-forming cell (ECFC)69. ECFCs are strictly defined as endothelial 
progenitors and are differentiated from “EPCs” based on specific criteria. These include: 1) 
The in vitro ability of cloned cells to form large colonies with high proliferative potential 
that can be re-cultured to form secondary colonies; 2) The in vivo capacity to form 
capillaries that anastomose with host vessels; 3) The in vitro capacity to form tubes with 
lumens when plated in collagen; 4) Absence of hematopoietic surface markers, but surface 
expression of other unique markers including CD31, CD146, CD144, CD105, CD34 
(partially), KDR, vWF, and lectins; and 5) Lack of phagocytic function. ECFCs or 
endothelial cells do not have phagocytic function, whereas “EPCs” or macrophages easily 
phagocytize E. coli fragments.
ECFCs are quite rare in CB (2 out of 108 CB MNCs); however, their numbers are relatively 
enriched in CB compared to adult PB. CB-ECFCs have long telomeres and their HPP is also 
much higher than adult PB-ECFC69. While the cells currently designated as EPCs are not 
true endothelial cells, they share similarities to the recently reported pro-angiogenic 
AC133+CD34+CD45dimlin− hematopoietic stem/progenitor cells and may contribute to 
neovascularization in cardiovascular disease or tumor progression70–72.
iPS and iPS-derived ECFC
Human iPS cells have been established in various human cells. Although CB does not 
contain truly pluripotent stem cells, CB can be induced into iPS cells when cultured in the 
presence of defined factors73;74. Cord blood iPS cells are hardy: a recent report showed that 
CB MNCs cryopreserved for over 20 years could still be utilized for HSC transplantation, 
ECFC isolation and the induction of iPS cells75. In addition, a novel culture system to 
produce ECFCs from human iPS has been established76. Human iPS derived-ECFCs display 
high clonal proliferative ability and have the capacity to form human vessels in mice. 
Importantly, these pluripotent cells can repair ischemic regions in mouse retina and limb 
injury models without inducing secondary teratoma formation. Thus, CB is useful not only 
for its stem cell populations but also for the induction of iPS cells that can be stored for 
future clinical use.
Stem Cells for the Treatment of Post-Insult Injury in Neonates
Neonates are highly susceptible to inflammatory and/or ischemic insults, particularly to 
critical organs such as the brain and lungs; this risk is considerably higher in the most 
immature, preterm infants77–79. The damaging and often permanent effects related to these 
newborn insults are associated with high economic and societal costs, while the personal 
suffering of the afflicted and their families is incalculable80;81. Thus, the successful 
prevention or treatment of insult-related injury is of utmost and immediate importance.
Neonatal injury and its inherent complications have been intensively studied for many years. 
Investigations in relevant animal models and human studies have advanced our 
understanding of the underlying mechanisms; however, treatments to prevent or to arrest 
injury as a result of these insults in many cases have been disappointing, until recently. A 
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growing body of evidence and exciting new discoveries indicate the potential (and in some 
cases, actual) regenerative role of SCT in the treatment of neonatal injury, as briefly 
reviewed below.
Brain injury and SCT
Hypoxic-ischemic encephalopathy—Studies in animal models have been critical to 
defining the mechanisms underlying post-insult brain injury. These models have been based 
on approaches that focus on either cellular/molecular mechanisms or that recapitulate the 
physiologic events that produce injury; these have been recently elegantly reviewed82. 
However, existing evidence has been distilled from studies using a spectrum of animal 
models and SCT approaches, primarily involving human amnion epithelial-derived cells 
(hAECs), MSC, whole cord blood and neural stem cells. Thus, the reparative benefits of 
SCT for post-insult brain injury and the specific cells involved remain unclearly defined 
(reviewed in83).
Umbilical cord blood is a repository of a plethora of stem cell types, including those of 
hematopoietic, endothelial and mesenchymal origin, as was discussed in the first part of this 
review. Rodent models of neonatal hypoxic-ischemic brain injury have exhibited structural 
and behavioral improvements following transplantation with human cord blood cells, 
including measurable improvements in cognition{de Paula S., 2012 19297 /id;Wasielewski, 
2012 20076 /id;Geissler, 2011 20087 /id}. However, the specific stem cell type(s) or cell 
combinations in cord blood that confer therapeutic properties have not been well defined. 
The underlying mechanisms are also unclear; evidence of poor engraftment in animals that 
respond positively to SCT suggest that the ameliorative effects are not due to the 
regenerative capabilities of the administered stem cells87. A relationship has been 
established between neuroprotection and indirect (paracrine and trophic) modulatory effects 
of administered stem cells, including MSCs and hAECs, on inflammatory and excitotoxic 
neural responses88;89. Administration of hAECs to sheep fetuses was also shown to confer 
protection from inflammation-induced brain injury90.
Studies of cord blood SCT in humans, while sparse, are increasing. In a recently reported 
prospective trial, 23 infants with hypoxic-ischemic encephalopathy received both head 
cooling and autologous cord blood transfusion within the first 72 hours of life91. The authors 
concluded that this form of SCT was both safe and feasible even in outborn infants 
transferred to a tertiary care hospital. However, no firm conclusions could be made 
regarding hospital and developmental outcomes or 1-year survival. In a feasibility pilot 
study, the transfusion of autologous cord blood from private cord blood banks to young 
children with neurologic disorders was found to be safe92. In a Korean study of 96 infants 
and children with cerebral palsy, subjects who received matched allogeneic cord blood cells 
with erythropoietin fared better developmentally six months later than did their counterparts 
given erythropoietin only or placebo93. Importantly, this study highlights the potential 
therapeutic utility of banked allogeneic donor cord blood cells in SCT of brain injury.
Neonatal stroke—Stroke is a primarily ischemic event that occurs in the fetal or neonatal 
periods and involves ischemia of cerebral arteries or periventricular venous infarction94. 
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Strokes in the perinatal period commonly (60% of cases) result in neurologic deficits, with 
hemiplegic cerebral palsy being a frequent complication. A variety of preclinical studies 
have shown potential therapeutic value of stem cell populations derived from human 
umbilical CB in limiting injury and in promoting functional recovery. In rodent stroke 
models, the administration of neural stem cells lead to glial and neuronal differentiation at 
sites of injury, while transplanted MSCs were indirectly beneficial by inducing the release of 
neuroprotective trophic factors that dampened inflammation95;96. Human CB-derived 
AC133+ EPCs limited infarct size and shortened the resolution period in a rat stroke 
model97. Stem cell types in addition to those derived from CB may also be of value. The 
administration of amniotic fluid-derived stem cells to adult rats with ischemic stroke also 
resulted in significant functional recovery98. However, the most beneficial stem cell type for 
the treatment of stroke remains unclear. Transplantation with the broader array of stem cells 
contained in human CD34+ cells bestowed a limited benefit in one rodent stroke model, 
while another study showed greater therapeutic effect and less inflammation in animals 
receiving CB mononuclear cells compared to CB MSCs99;100. While the potential 
therapeutic utility of SCT in neonates with stroke is supported by preclinical studies, 
however its actual utility in human neonates, while promising, remains to be defined101.
Lung injury and SCT
Extremely preterm infants are at high risk for numerous long-term complications, of which 
bronchopulmonary dysplasia (BPD) is the most common102. The “new” BPD is associated 
with lung growth arrest as well as abnormal vascularization and fibrosis, and it can result in 
disabling lung abnormalities that persist into adulthood79. Studies in neonatal animal models 
of BPD have shown that transplantation with MSC or soluble MSC-derived proteins (the 
MSC “secretome”) can modulate BPD by dampening inflammatory processes96;103–105. In a 
recently reported phase I dose-escalation trial, a small group of extremely preterm infants 
who received intra-tracheal autologous MSC had diminished BPD severity and lowered 
inflammatory cytokine levels in tracheal aspirates compared to historical controls106. 
Importantly, MSC treatment was clinically well tolerated in these tiny babies and was not 
associated with discernable short-term safety issues. The potential benefits of cord blood 
MSCs have stimulated numerous ongoing clinical trials addressing their use for the 
treatment of diverse disorders in adults and several in preterm infants.
Intestinal injury and SCT
Necrotizing enterocolitis (NEC), an intestinal inflammatory disorder with infectious 
components, is a common and potentially devastating complication of prematurity107. The 
etiology of NEC is multifactorial and includes ischemia-reperfusion injury, disturbances of 
the intestinal microbiome and prior inflammatory exposure. The potential role of SCT in the 
treatment of neonatal NEC has only recently been addressed. In an in vivo neonatal rat 
model of NEC, intraperitoneal administration of bone-marrow derived MSCs was associated 
with attenuated histologic intestinal injury, improved weight gain, and decreased clinical 
illness scores108. MSC homing to intestinal tissue was enhanced in the pups with NEC 
compared to normal controls, suggesting a potentiating role for inflammation in the 
engraftment of MSC. In another study, neonatal rats with NEC that were treated with 
amniotic fluid stem cells showed improved gut structure, survival and reduced inflammatory 
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mechanisms mediated via COX-2109. Despite these encouraging preclinical data, a role for 
SCT in the treatment of NEC in human neonates has not been reported to date.
Utility of Neonatal SCT: General Considerations
A number of critical questions remain to be answered through well-designed pre-clinical 
large animal models and human clinical trials before the use of umbilical CB or specific 
stem cells afford reasonable therapeutic options. One important issue is that of the optimal 
timing of SCT administration in the context of the injury. Studies in infants with brain injury 
have shown a secondary post-injury period during which inflammatory and excitatory 
mechanisms become pronounced, thus the time between the initial insult and this later phase 
may be the ideal window to institute SCT as a therapeutic measure110. Conversely, a Korean 
study showed benefit of SCT in children with cerebral palsy, even in those who were 10 
years of age111, which suggests a possible benefit despite long-standing neurologic injury.
Another key issue to be addressed is the identification of the ideal stem cell source for a 
specific type of tissue injury. As detailed earlier in this review, umbilical cord blood 
contains numerous stem cell types, including those of hematopoietic, endothelial, and 
mesenchymal origins. However, it remains unclear if and how the perinatal factors 
contributing to neonatal hypoxic-ischemic encephalopathy or other injury could potentially 
influence the functionality and intrinsic properties of the cord blood stem cells 
themselves112.
The role of specific stem cell types in various target organs also remains incompletely 
defined. Mesenchymal stem cells (MSC) derived from developing humans exhibit a high 
degree of mesodermal pluripotency (the capacity to differentiate into multiple cell types); in 
addition, these MSC are associated with a low induction of immune responses in the 
recipient and exhibit anti-inflammatory properties96;113. Another type of cell with 
pluripotent properties is the hAEC114. Like MSCs, hAECs are anti-inflammatory and appear 
to be immunologically well-tolerated115;116. Studies in fetal sheep showed that AEDC 
administration was protective against brain inflammation, including periventricular white 
matter injury90. As also observed with MSCs, the beneficial effect of hAECs may be 
primarily related to the release of soluble protective factors87.
In addition to the optimal stem cell type and timing of administration necessary for 
therapeutic efficacy, other questions that remain to be answered include: the most ideal stem 
cell sources (autologous versus allogeneic, cord blood versus isolated stem cells, primary 
cells versus derived or genetically modified cells), host tolerance, and safety, among 
others110;117. While short-term safety may be acceptable, as suggested by the very small 
number of recent human studies, long-term effects remain unknown. This latter point may 
be of particular importance to very preterm infants who are still undergoing developmental 
maturation, including of the immune and hematopoietic systems. Another critical safety 
feature to be defined involves the potential tumorgenicity or cancerous conversion of the 
transplanted stem cells, a question that remains enigmatic.
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Summary
True stem cells or cells with pluripotent properties are found in a variety of tissues and 
organs. Umbilical cord blood can provide a spectrum of stem or pluripotent progenitor cells, 
many of which have a greater potential for proliferation (although not necessarily 
engraftment) compared to similar cells mobilized from the bone marrow into the peripheral 
blood of adults. Preclinical studies have shown a therapeutic benefit of SCT in perinatal and 
neonatal injuries, including those involving the brain, lungs and intestines. The very few 
human studies to date suggest short-term safety of MSCs or cord blood (both autologous and 
allogeneic) SCT and have variably shown measurable improvements in functional or 
inflammatory parameters. However, the therapeutic mechanisms remain incompletely 
defined, and the optimal usage of SCT for a particular type of injury is also unclear. Thus, 
despite its exciting potential for currently untreatable neonatal disorders, extensive studies in 
both preclinical models and in humans will be necessary before SCT becomes an accepted 
form of therapy. Although still quite limited relative to studies in adults, an increasing 
number of human trials now address these issues in neonates (https://ClinicalTrials.gov).
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Key Points
• Umbilical cord blood contains a plethora of stem cells and multipotent 
progenitor cells.
• In preclinical animal models, transplantation with cord blood or specific stem-
like cells can limit brain and lung injury and/or preserve or restore function in 
part through anti-inflammatory mechanisms.
• The small number of human studies to date suggests the short-term safety of 
cord blood-derived stem cells, however additional preclinical and human studies 
are needed to establish therapeutic efficacy and long-term safety.
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Figure 1. Hematopoietic hierarchy system
Long-term hematopoietic stem cells (Lt-HSCs) sit on the apex of the hematopoietic 
hierarchy system. LT-HSCs that reside in the bone marrow hematopoietic niche maintain 
self-renewal and multi-lineage differentiation capacity through asymmetric cell division. 
SH-HSC: short-term hematopoietic stem cell, MPP: multipotent progenitor cell, MLP: 
multilymphoid progenitor cell, CMP: common myeloid progenitor cell, ETP: earliest T 
lymphoid progenitor cell, GMP: granulocyte-macrophage progenitor cell, MEP: 
megakaryocyte-erythroid progenitor cell.
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